Computer-aided detection (CAD) developer Deus Technologies may be close to Food and Drug Administration approval for its RapidScreen RS-2000 lung cancer detection device. The FDA's radiological devices panel has recommended its approval as a device to aid in the detection of early-stage lung cancer.
The panel's unanimous decision came after a public hearing on March 5 at the agency's Gaithersburg, MD, facility. The FDA is expected to act on the panel's recommendation of approval by early April, according to Deus.
RS-2000 is a computer-aided detection (CAD) system that digitizes and analyses chest x-rays to identify regions of interest (ROIs) that may have features associated with early-stage lung cancer. The system utilizes existing PA or AP chest radiographs to help identify suspicious areas that may warrant a second review, according to Deus.
By AuntMinnie.com staff writersMarch 27, 2001
Copyright © 2001 AuntMinnie.com
